KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accumulated Expenses: 2020-2023

Historic Accumulated Expenses for AbCellera Biologics (ABCL) over the last 3 years, with Sep 2023 value amounting to $3.1 million.

  • AbCellera Biologics' Accumulated Expenses fell 82.64% to $3.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $3.1 million, marking a year-over-year decrease of 82.64%. This contributed to the annual value of $19.3 million for FY2022, which is 14.04% down from last year.
  • Per AbCellera Biologics' latest filing, its Accumulated Expenses stood at $3.1 million for Q3 2023, which was down 0.00% from $3.1 million recorded in Q2 2023.
  • Over the past 5 years, AbCellera Biologics' Accumulated Expenses peaked at $50.6 million during Q2 2022, and registered a low of $595,000 during Q3 2021.
  • Its 3-year average for Accumulated Expenses is $19.0 million, with a median of $19.3 million in 2022.
  • As far as peak fluctuations go, AbCellera Biologics' Accumulated Expenses surged by 2,895.29% in 2022, and later slumped by 93.88% in 2023.
  • AbCellera Biologics' Accumulated Expenses (Quarterly) stood at $27.1 million in 2020, then declined by 17.08% to $22.5 million in 2021, then dropped by 14.04% to $19.3 million in 2022, then plummeted by 82.64% to $3.1 million in 2023.
  • Its Accumulated Expenses stands at $3.1 million for Q3 2023, versus $3.1 million for Q2 2023 and $3.1 million for Q1 2023.